<DOC>
	<DOCNO>NCT00510107</DOCNO>
	<brief_summary>To evaluate efficacy safety weekly administer combination docetaxel/cisplatin docetaxel/oxaliplatin chemotherapy-na√Øve patient advance gastric cancer . The primary endpoint response rate .</brief_summary>
	<brief_title>Weekly Docetaxel Plus Cisplatin Oxaliplatin AGC</brief_title>
	<detailed_description>Gastric cancer frequently occur malignancy Korea , one main cause cancer death . While treatment option AGC expand recent year include new agent taxanes , irinotecan oxaliplatin , myelosuppression remain problem . Recently , weekly schedule docetaxel appeal due limited incidence severe myelosuppression compare standard 3-weekly regimen . This altered toxicity profile suggest potential good tolerance increase dose intensity .</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>histologically proven gastric cancer age 75 year less performance status 0 2 prior chemotherapy inoperable , recurrent , metastatic normal marrow , hepatic renal function active infection severe comorbidities pregnant lactate woman active brain metastasis neuropathy grade 2 high</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2007</verification_date>
</DOC>